로딩 중…
지수 로딩 중…
Celltrion, Inc.
068270· KOSPI· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩170,300-1.90%
2026-06-19
Price Chart
Celltrion, Inc.+11.53%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 37.74T KRW |
| Revenue | 4.47T KRW |
| Net Income | 1.27T KRW |
| Total Assets | 23.16T KRW |
| Net Assets | 17.81T KRW |
| Employees | 2,901 |
| Value | |
| P/E | 29.65x |
| P/B | 2.12x |
| PEG | 0.13x |
| P/S | 8.45x |
| EV/EBITDA | 29.98x |
| FCF Yield | 1.34% |
| Profitability | |
| ROE | 7.15% |
| ROA | 5.50% |
| Op. Margin | 30.03% |
| Revenue Growth | 36.00% |
| Earnings Growth | 222.93% |
| Financial Health | |
| Debt Ratio | 29.99% |
| Total Debt | 3.74T KRW |
| FCF | 506.77B KRW |
| Cash | 1.29T KRW |
| Current Ratio | 1.39x |
| Net Debt/EBITDA | 1.83x |
| Dividend | |
| Div. Yield | 0.41% |
| Div. Growth | 0.00% |
| Performance | |
| 1Y Return | 11.53% |
| 1M Return | -0.41% |
| From 52W High | -28.82% |
| 1Y MDD | -32.70% |
| Trading | |
| Volume | 1,135,952 shares |
| Foreign Own. | 24.36% |
| Per Share | |
| EPS | 5,226 KRW |
| BPS | 76,797 KRW |
Company Info
Celltrion, established in 1991, completed its KOSDAQ listing in 2005 and transferred to the Securities Market in 2018, building a unified corporate structure through the absorption merger of Celltrion Healthcare in 2023. It develops, produces, and sells antibody drugs using biotechnology and animal cell mass culture technology, possessing an 11-product portfolio. The company is strengthening its next-generation antibody drug pipeline through alliances and investments with global biotech companies. Celltrion is headquartered in Yeonsu-gu, Incheon Metropolitan City.